Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

Université de Montréal

$17,500.00

Chemogenomic Vulnerabilities of Pre-Leukemic Stem Cells in Lymphoblastic Leukemia

FY 2019-20

Summary
"Acute lymphoblastic leukaemia (ALL) is the most common blood cancer observed in young children. An adult onset can be observed, albeit more rarely . My project aims to improve current chemotherapy regimen for T-cell acute lymphoblastic leukaemia, which corresponds to a sub-type of ALL in which there is aberrant proliferation of specific white blood cells called T lymphocytes (or T cells). Despite its success, chemotherapy for T-ALL is extremely harsh with both physical and psychological consequences that are difficult to overcome, especially when treatments have to be administered over the course of two to four years. This long treatment is required to eliminate fast-proliferating cells, but also to target pre-leukaemic stem cells hiding in the thymus and that are unfortunately not as sensitive to current chemotherapeutic drugs. The objective of my research is to boost the efficacy of chemotherapy on these drug-resistant cells by adding a novel drug to sensitize these cells to the mainstay drug regimen. Such a drug acts on specific vulnerabilities of pre-leukemic stem cells that have been uncovered by this research and that are not present in normal cells. A more effective chemotherapy regimen may improve current treatments such that they become less disabling and improve patient quality of life."
Program
Master's Award: Canada Graduate Scholarships
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
428698
Name
Badrudin Irfan Mathieu
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Chemogenomic Vulnerabilities of Pre-Leukemic Stem Cells in Lymphoblastic Leukemia
Programtype2
Studentship Programs
Orgnameinp2
Université de Montréal
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Acute Lymphoblastic Leukemia; Cell Co-Culture; Chemogenomics; Chemotherapy; Flow Cytometry; Pre-Leukemic Stem Cells; Synthetic Lethality; Transgenic Mouse Model; Western Blotting
Abstract
"Acute lymphoblastic leukaemia (ALL) is the most common blood cancer observed in young children. An adult onset can be observed, albeit more rarely . My project aims to improve current chemotherapy regimen for T-cell acute lymphoblastic leukaemia, which corresponds to a sub-type of ALL in which there is aberrant proliferation of specific white blood cells called T lymphocytes (or T cells). Despite its success, chemotherapy for T-ALL is extremely harsh with both physical and psychological consequences that are difficult to overcome, especially when treatments have to be administered over the course of two to four years. This long treatment is required to eliminate fast-proliferating cells, but also to target pre-leukaemic stem cells hiding in the thymus and that are unfortunately not as sensitive to current chemotherapeutic drugs. The objective of my research is to boost the efficacy of chemotherapy on these drug-resistant cells by adding a novel drug to sensitize these cells to the mainstay drug regimen. Such a drug acts on specific vulnerabilities of pre-leukemic stem cells that have been uncovered by this research and that are not present in normal cells. A more effective chemotherapy regimen may improve current treatments such that they become less disabling and improve patient quality of life."
Competitiondate
201912
Approvedterm2
1 yr 0 mth
Pinamesdelim
Badrudin, Irfan Mathieu
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~